Positron emission tomography (PET) for diagnosis and monitoring of treatment for urological tumors;Positronenemissionstomographie (PET) zur diagnostik und zum therapiemonitoring bei urologischen tumoren

Urologe - Ausgabe A

Volumn 43, Issue 11, 2004, Pages 1397-1409

  Machtens, S ^a   Boerner, A R ^a   Hofmann, M ^b   Knapp, W H ^a   Jonas, U ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Bladder cancer; Germ cell cancer; PET; Prostate cancer; Renal cell cancer

Indexed keywords

ACETIC ACID; CHOLINE; FLUORODEOXYGLUCOSE F 18;

BLADDER CANCER; BONE METASTASIS; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC PROCEDURE; EVALUATION; FOLLOW UP; GERM CELL TUMOR; HUMAN; INTERMETHOD COMPARISON; KIDNEY CANCER; LABORATORY DIAGNOSIS; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROBABILITY; PROSTATE CANCER; REVIEW; SEMINOMA; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TERATOMA; TESTIS CANCER; URINARY TRACT CANCER; VALIDATION PROCESS;

ALGORITHMS; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; UROGENITAL NEOPLASMS; UROLOGIC NEOPLASMS; UROLOGY;

EID: 12344291077     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-004-0714-3     Document Type: Review

References (79)

1. Albers P, Bender H, Yilmaz H, Schoenreich G, Biersack HJ, Mueller SC (1999) Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors. Urology 53: 808-811
2. Bachor R, Kotzerke J, Gottfried HW et al. (1996) Positronen-Emissions- Tomographie in der Diagnose von Nierenzellkarzinomen. Urologe A 1996: 146-150
3. Bachor R, Kotzerke J, Reske SN, Hautmann R (1999) Lymph node staging of bladder neck carcinoma with positron emission tomography. Urologe A 38: 46-50
4. Bokemeyer C, Kollmannsberger C, Oechsle K et al. (2002) Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [18F]FDG PET. Br J Cancer 86: 506-511
5. Chang CH, Wu HC, Tsai JJP, Shen YY, Changlai SP, Kao A (2003) Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol Int 70: 311-315
6. Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I (1998) Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16: 3375-3379
7. Costello LC, Franklin RB (1997) Citrate metabolism of normal and malignant prostate epithelial cells. Urology 50: 3-12
8. Cremerius U, Effert PJ, Adam G et al. (1998) FDG PET for detection and control of metastatic germ cell tumor. J Nucl Med 39: 815-22
9. Cremerius U, Wildberger JE, Borchers, Zimny M, Jakse G, Gunth RW, Buell U (1999) Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients. Urology 54: 900-904
10. de Jong IJ, Pruim J, Elsinga PH (2002) Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol 42: 18-23
11. De Santis M, Becherer A, Bokemeyer C et al. (2001) Predictive impact of 2-18Fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 19: 3740-3744
12. De Santis M, Becherer A, Bokemeyer C et al. (2004) 2-18fluoro-deoxy-D- glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 22: 1034-1039
13. De Santis M, Pont J (2004) The role of positron emission tomography in germ cell cancer. World J Urol 22: 41-46
14. Effert PJ, Bares R, Handt S, Wolff JM, Bull U, Jakse G (1996) Meatbolic imaging of untreated prostate cancer by positron emission tomography with 18 fluorine-labelled deoxyglucose. J Urol 155: 994-998
15. Fernandez EB, Moul JW, Foley JP, Colon E, McLeod DG (1994) Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors. Urology 44: 548-552
16. Fricke E, Machtens S, Hofmann M et al. (2003) Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imag 30: 607-611
17. Ganjoo KN, Chan RJ, Sharma M, Einhorn LH (1999) Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J Clin Oncol 17: 3457-3460
18. Goldberg MA, Mayo-Smith WW, Papanicolaou N (1997) FDG PET characterization of renal masses: preliminary experience. Clin Radiol 52: 510-515
19. Grossfeld GD, Stier DM, Flanders SC (1998) Use of second treatment following definitive local therapy for prostate cancer: data from the CaPSURE database. J Urol 160: 1398-1404
20. Hain SF, O'Doherty MJ, Timothy AR, Leslie M, Harper P, Hudart R (2000) Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumors at relapse. Br J Cancer 83: 863-869
21. Hain SF, O'Doherty MJ, Timothy AR (2000) Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med 27: 590-594
22. Hara T, Kosaka N, Kishi H (1998) PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39: 990-995
23. Heicapell R, Müller-Mattheis V, Reinhardt M (1999) Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18F)]-2-deoxy-D-glucose. Eur Urol 36: 582-587
24. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M (1999) Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 36: 31-35
25. Hofer C, Kübler H, Hartung R, Breul J, Avril N (2001) Diagnosis and monitoring of urological tumors using positron emission tomography. Eur Urol 40: 481-487
26. Hogeboom WR, Hoekstra HJ, Mooyaart EL, Sleijfer DT, Schraffordt Koops H (1993) Magnetic resonance imaging of retroperitoneal lymph node metastases of non-seminomatous germ cell tumors of the testis. Eur J Surg Oncol 19: 429-437
27. Hoh C, Figlin R, Belldegrun A (1996) Evaluation of renal cell carcinoma with whole body FDG PET. J Nucl Med 37: 141
28. Horwich A, Alsanjari N, A'Hern R (1992) Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer 65: 775-778
29. Hosten N, Stroszczynski C, Rick O, Lemke M, Felix R (1999) Retroperitoneale Rezidive nicht-seminomatöser Hodentumoren: Computertomographische Befunde vor retroperitonealer Lymphadenektomie. Fortschr Röntgenstr 170: 61-65
30. Jadvar H, Kherbache HM, Pinski JK, Conti PS (2003) Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma. Clin Nephrol 60: 395-400
31. Kanamaru H, Oyama N, Akino H, Okada K (2000) Evaluation of prostate cancer using FDG-PET. Hinyokika Kiyo 46: 851-853
32. Kang DE, White RL Jr, Zuger JH, Sasser HC, Teigland CM (2004) Clinical use of Fluorodeoxyglucose F18 Positron Emission Tomography for detection of renal cell carcinoma. J Urol 171: 1806-1809
33. Karapetis CS, Strickland AH, Yip D, Steer C, Harper PG (2003) Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-center experience with long-term follow-up. Int Med 33: 427-435
34. Kato T, Tsukamato E, Kuge Y et al. (2002) Accumulation of (11C) acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med 29: 1492-1495
35. Kocher F, Grimmel S, Hautmann R (1994) Preoperative lymph node staging in patients with kidney and urinary bladder neoplasm. J Nucl Med 35 [Suppl]: 233
36. Kollmannsberger C, Oechsle K, Dohmen BM et al. (2002) Prospective comparison of [18F] fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer 94: 2353-2362
37. Kosuda S, Kison PV, Greenough R, Grossman HB, Wahl RL (1997) Preliminary assessment of fluorine-18fluorodeoxyglucose positron emisson tomography in patients with bladder cancer. Eur J Nucl Med 24: 615-620
38. Kotzerke J, Prang J, Neumaier B (2000) Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 27: 1415-1419
39. Kotzerke J, Volkmer BG, Glatting G et al. (2003) Intraindividual comparison of [11C] acetate and [11C] choline PET for detection of metastases of prostate cancer. Nuklearmedizin 42: 25-30
40. Lassen U, Daugaard G, Eigtved A, Hojgaard L, Damgaard K, Rorth M (2003) Whole body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging 30: 396-402
41. Levine E (1995) Renal cell carcinoma: clinical aspects, imaging diagnosis, and staging. Semin Roentgenol 30: 128-148
42. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK (2001) Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 57: 108-111
43. Majhail NS, Urbain JL, Albani JM et al. (2003) F-18 Fluordeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 21: 3995-4000
44. Maszelin P, Lumbroso J, Theodore C, Foehrenbach H, Merlet P, Syrota A (2000) Fluorodeoxyglucose (FDG) positron emission tomography (PET) in testicular germ cell tumors in adults: preliminary French clinical evaluation, development of the technique and its clinical applications. Prog Urol 10: 1190-1199
45. McLeod DG, Weiss RB, Stablein DM (1991) Staging relationship and outcome in early stage testicular cancer: a report from the Testicular Intergroup Study. J Urol 145: 1178-1183
46. Miyakita H, Tokunaga M, Onda H et al. (2002) Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol 9: 15-18
47. Miyauchi T, Brown RS, Grossman HB (1996) Correlation between visualization of primary renal cancer by FDG-PET and histopathological findings. Annual Meeting of the Society of Nuclear Medicine, 43, p 245
48. Morris MJ, Akhurst T, Osman I (2002) Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 59: 913-918
49. Müller-Matheis V, Reinhardt M, Gerharz CD, Fürst G, Vosberg H, Müller-Gärtner H-W, Ackermann R (1998) Die Positronenemissionstomography mit [18F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) bei der Diagnose retroperitonealer Lymphknotenmetastasen von Hodentumoren. Urologe A 37: 609-620
50. Nunez R, Macapinlac HA, Yeung HW et al. (2002) Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 43: 46-55
51. Nuutinen JM, Lekinen S, Elomaa I et al. (1996) Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET. Eur J Cancer 33: 1234-1241
52. Oyama N, Akino H, Kanamaru H, Okada K (1998) Fluorodeoxyglucose positron emission tomography in diagnosis of untreated prostate cancer. Nippon Rinsho 56: 2052-2055
53. Oyama N, Akino H, Suzuki Y, Kanamaru H, Sadato N, Yonekura Y, Okada K (1999) The increased accumulation of [18F] fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 29: 623-629
54. Oyama N, Akino H, Suzuki Y (2001) FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun 22: 963-969
55. Oyama N, Akino H, Kanamaru H et al. (2002) 11C-acetate PET imaging of prostate cancer. J Nucl Med 43: 181-186
56. Oyama N, Miller TR, Dehdashti F et al. (2003) 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 44: 549-555
57. Pfannenberg AC, Oechsle K, Bokemeyer C et al. (2004) The role of [18F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of postchemotherapy residual masses in the metastatic germ cell tumors - prospects for management. Worl J Urol 22: 132-139
58. Picchio M, Messa C, Landoni C et al. (2003) Value of [11C] choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F] flurodeoxyglucose-positron emission tomography. J Urol 169: 1337-1340
59. Price DT, Coleman RE, Liao RP (2002) Comparison of [18F] fluorocholine and [18F] fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 168: 273-280
60. Ramdave S, Thomas GW, Berlangiere SU et al. (2001) Fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001: 825-830
61. Safaei A, Figlin R, Hoh CK, Silverman DH, Seltzer M, Phelps ME, Czernin J (2002) The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer. Clin Nephrol 57: 56-62
62. Sanchez D, Zudaire JJ, Fernandez JM et al. (2002) 18F-fluoro-2- deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse. BJU Int 89: 912-916
63. Sanz G, Robles JE, Gimenez M (1998) Positron emission tomography with 18fluorine-labeled deoxyglucose: utility in localized and advanced prostate cancer. Br J Urol 84: 1028-1031
64. Schultz SM, Einhorn LH, Conces DJ, Williams SD, Loehrer J (1989) Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol 7: 1497-1503
65. Seto E, Segall GM, Terris MK (2000) Positron emission tomography detection of osseous metastases of renal cell carcinoma not identified on bone scan. Urology 55: 286-291
66. Seltzer MA, Barbaric Z, Belldegrun A et al. (1999) Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 162: 1322-1328
67. Shreve PD, Grossman HB, Gross MD, Wahl RL (1996) Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18] fluoro-D-glucose. Radiology 199: 751-756
68. Spermon JR, De Geus-Oei LF, Kiemeney LALM, Witjes JA, Oyen WJG (2002) The role of 18F-fluoro-2-deoxyglucose-positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int 89: 549-556
69. Stephens AW, Gonin R, Hutchins GD, Einhorn LH (1996) Positron emission tomography evaluation of residual radiographic abnormalities in postchemotheapy germ cell tumors patients. J Clin Oncol 14: 1637-1641
70. Stomper PC, Kalish LA, Garnick MB, Richie JP, Kantoff PW (1991) CT and pathologic predictive features of residual mass histological findings after chemotherapy for nonseminomatous germ cell tumors: can residual malignancy or teratoma be excluded? Radiology 180: 711-714
71. Strauss LG (1996) Fluorine-18 deoxyglucose and false positive results: a major problem in the diagnosis of oncological patients. Eur J Nucl Med 23: 1409-1415
72. Sugarawa Y, Zasadny KR, Grossman HB, Francis IR, Clarke MF, Wahl RL (1999) Germ cell tumor:differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling. Radiology 211: 249-256
73. Sung J, Espiritu JI, Segall GM, Terris MK (2003) Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cnacer. BJU Int 92: 24-27
74. Tsatalpas P, Beuthien-Baumann B, Kropp J et al. (2002) Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors. Urol Int 68: 157-163
75. Wahl RL, Harney J, Hutchins G, Grossman HB (1991) Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose: pilot animal and human studies. J Urol 146: 1470-1474
76. Wilson CB, Young HE, Ott RJ, Flower MA, Cronin BF, Pratt BE, McCready VR, Norwich A (1995) Imaging metastatic testicular germ cell tumors with 18FDG positron emission tomography: prospects of detection and management. Eur J Nucl Med 22: 508-513
77. Wu HC, Yen RF, Shen YY, Kao CH, Lin CC, Lee CC (2002) Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphospate bone scan to detect bone metastases in patients with renal cell carcinomas - a preliminary report. J Cancer Res Clin Oncol 128: 503-506
78. Yeh SD, Imbriaco M, Larson SM (1996) Detection of bony metastases of androgen independent prostate cancer by PET-FDG. Nucl Med Biol 23: 693-697
79. Yoshimoto M, Waki A, Yonekura Y et al. (2001) Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 28:117-122